Chemical Structure : GSK2033
CAS No.: 1221277-90-2
Catalog No.: PC-63084Not For Human Use, Lab Use Only.
GSK2033 (GSK 2033) is the first potent, cell-active LXR antagonist with binding pIC50 of 7.0/7.5 for LXRα/LXRβ, respectively.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 5 mg | $88 | In stock | |
| 10 mg | $128 | In stock | |
| 25 mg | $218 | In stock | |
| 50 mg | $358 | In stock | |
| 100 mg | Get quote |
Bulk size, bulk discount!
Welcome credit card payment!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
GSK2033 (GSK 2033) is the first potent, cell-active LXR antagonist with binding pIC50 of 7.0/7.5 for LXRα/LXRβ, respectively.
GSK2033 suppresses GC-induced gluconeogenic gene expression without affecting immune-responsive GR target genes.
GSK2033 displays unexpected activity in the mouse NAFLD model.
| M.Wt | 591.66 | |
| Formula | C29H28F3NO5S | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
2,4,6-Trimethyl-N-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-N-[[5-(trifluoromethyl)-2-furanyl]methyl]benzenesulfonamide |
|
1. Zuercher WJ, et al. J Med Chem. 2010 Apr 22;53(8):3412-6.
2. Griffett K, et al. Biochem Biophys Res Commun. 2016 Oct 21;479(3):424-428.
3. Patel R, et al. Endocrinology. 2017 Apr 1;158(4):1034-1047.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright